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Abstract
 
Toll-like receptors (TLRs) and members of the proinflammatory interleukin 1 receptor (IL-1R)
family are dependent on the presence of MyD88 for efficient signal transduction. The bipartite
nature of MyD88 (
 
N
 
-terminal death domain [DD] and COOH-terminal Toll/IL-1 receptor
[TIR] domain) allows it to link the TIR domain of IL-1R/TLR with the DD of the Ser/Thr
kinase termed IL-1R–associated kinase (IRAK)-1. This triggers IRAK-1 phosphorylation and
in turn the activation of multiple signaling cascades such as activation of the transcription factor
nuclear factor (NF)-
 

 
B. In contrast, expression of MyD88 short (MyD88s), an alternatively
spliced form of MyD88 that lacks only the short intermediate domain separating the DD and
TIR domains, leads to a shutdown of IL-1/lipopolysaccharide-induced NF-
 

 
B activation.
Here, we provide the molecular explanation for this difference. MyD88 but not MyD88s
 
strongly interacts with IRAK-4, a newly identified kinase essential for IL-1R/TLR signaling.
 
In the presence of MyD88s, IRAK-1 is not phosphorylated and neither activates NF-
 

 
B nor is
ubiquitinated. Thus, MyD88s acts as a negative regulator of IL-1R/TLR/MyD88-triggered sig-
nals, leading to a transcriptionally controlled negative regulation of innate immune responses.
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
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Introduction
 
IL-1R–associated kinase (IRAK)-1 was originally identi-
fied as a protein kinase that associates with the IL-1Rs (a
heterocomplex composed of the IL-1RI and IL-1RAcP)
after IL-1 stimulation (1, 2). It is now known to play an
important role in the activation of NF-
 

 
B and mitogen-
activated protein kinase signaling cascades initiated by IL-1
 

 
and Toll-like receptor (TLR) ligands (3, 4). Stimulation
triggers the rapid recruitment of IRAK-1 to an activated
receptor resulting in IRAK-1 hyperphosphorylation. Phos-
phorylation of IRAK-1 appears necessary for signal trans-
duction. It is required for binding to TNFR-associated fac-
tor 6 and for the formation of a multiprotein signalosome
that is crucial for driving the activation of the transcription
factors activator protein 1 (AP1) and nuclear factor (NF)-
 

 
B
(5–8). Phosphorylation of IRAK-1 also leads to its protea-
some-mediated degradation, the function of which is un-
clear but might be a means of switching off or terminating
the signal (9, 10).
The MyD88 short (MyD88s) protein (MyD88 without
the intermediary domain (ID), amino acids 110–157) can
be detected only after continuous stimulation with bacterial
products (i.e., LPS) or proinflammatory cytokines (i.e.,
TNF
 

 
; reference 11). This inducible expression hints to its
role as a negative regulator of Toll/IL-1 receptor (TIR)
signaling that we previously proposed based on its ability to
block IL-1/LPS-induced NF-
 

 
B activation. Like MyD88,
MyD88s binds both the IL-1R and IRAK-1, but in con-
trast to MyD88, ectopic expression of MyD88s does not
induce IRAK-1 phosphorylation (11). This suggested a po-
tential mechanism for the inhibitory effect of MyD88s and
that MyD88 via its ID might activate and/or bind a kinase
required for IRAK-1 phosphorylation.
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Materials and Methods
 
Biological Reagents and Cell Culture.
 
Recombinant mouse
TNF
 
 
 
and IL-1
 
 
 
were provided by Apotech and Sigma-Aldrich,
respectively. The source of the various antibodies used in this
study is as follows: anti-Flag/M2 (Eastman Kodak Co.), anti–
vesicular stomatitis virus (VSV; Sigma-Aldrich), anti–IRAK-1
(Qbiogene or Santa Cruz Biotechnology, Inc.), anti-MyD88
(ProSci Inc.), and anti-E (Amersham Biosciences) antibodies.
293T and the embryonic cell lines were maintained in DMEM
Glutamax supplemented with 10% fetal calf serum and 100 
 

 
g
penicillin/streptomycin.
 
Generation of MyD88
 
 
 
Mouse Embryo Fibroblasts (MEFs).
 
D14 MEFs from MyD88
 
 
 
were transformed by transfection
with a vector encoding the SV40 T antigen (provided by F.
Radtke, Institute Ludwig, Epalinges, Switzerland). These cells
were then reconstituted with MyD88, MyD88s, or empty vector
by retroviral infection. Populations of MyD88 or MyD88s recon-
stituted cells (called MEF
 
 
 
MyD88 and MEF
 
 
 
MyD88s, respec-
tively) were selected with 1 
 

 
g/ml puromycin.
 
Expression Vectors and Yeast 2 Hybrid Constructs.
 
Expression
vectors encoding IRAK-1, IRAK-1 D340N, MyD88, and
MyD88s have been previously described (11, 12). IRAK-4 was
PCR amplified from an expressed sequence tag (EST) clone and
inserted into pCRIII containing an NH
 
2
 
-terminal Flag or a VSV
tag, or inserted into pGAD10. Kinase-dead mutants of IRAK-4
(IRAK-4KK213AA or IRAK-4D311N) were generated by dou-
ble PCR and inserted into a pCRIII vector with an NH
 
2
 
-terminal
tag. pGBT9 MyD88, pGBT9 MyD88-N (amino acids 1–172),
and pGBT9 MyD88-TIR (amino acids 161–296) expressing
pGALDB (the GAL4 DNA-binding domain) fused to full-length
MyD88 or the indicated deletion mutants have been described
previously (13). pGBT9 MyD88-ID (amino acids 110–157) and
pGBT9 MyD88-death domain (DD; amino acids 1–110) were
prepared by inserting PCR-generated fragments into pGBT9.
The sequence of all PCR-generated cDNAs were confirmed
by DNA sequencing. pGAD10 IRAK-4–expressing Gal4AD-
IRAK4 (a fusion protein of GAL4 transcription activation with
full-length IRAK-4) was made by inserting IRAK-4 cDNA as an
EcoRI fragment into pGAD10.
 
Yeast 2 Hybrid Interaction Studies.
 
Interaction of full-length
IRAK-4 with different deletion mutants of MyD88 was evalu-
ated by yeast 2 hybrid interaction studies, performed as previously
described (14). In brief, yeast cells of the 
 
Saccharomyces cerevisiae
 
strain HF7c were cotransformed with the pGAD10 IRAK-4 and
pGBT9 MyD88 or pGBT9 fused to different MyD88 deletion
mutants (schematically illustrated in Fig. 3 B). Transformation ef-
ficiency was verified by growth on appropriate synthetic media
using Trp and Leu selection markers. Protein interaction was re-
vealed by His auxotrophy and assessed by 
 
 
 
galactosidase expres-
sion filter assays. 
 
 
 
indicates strong color development within
60 min of the assay and 
 
 
 
indicates no development of color
within 24 h. All pGBT9 MyD88 fusion proteins were negative
for autoactivation.
 
Immunoprecipitation and Kinase Assays.
 
Transfected 293T cells
were lysed in lysis buffer (1% NP-40, 20 mM Hepes, pH 7.9, 250
mM NaCl, 20 mM 
 
 
 
glycerophosphate, 10 mM NaF, 1 mM so-
dium orthovanadate, 2 mM dithiothreitol, 1 mM EDTA, and a
protease inhibitor cocktail). After lysis, the cell extracts were in-
cubated with one of the following antibodies for 2 h at 4
 
	
 
C: 1 
 

 
g
anti-M2, anti-VSV, anti-IRAK-1, or anti-E preincubated with
protein G Sepharose. After incubation the beads were washed six
times with lysis buffer, separated by SDS-PAGE, transferred to
nitrocellulose, and analyzed by immunoblotting.
 
For the kinase assays, transiently transfected HEK 293T cells
were lysed in 500 
 

 
l of 20 mM Tris, pH 7.5, 50 mM KCl, 5
mM MgCl
 
2
 
, 400 mM NaCl, 2 mM dithiothreitol, 1% Triton
X-100, 20% glycerol, and protease and phosphatase inhibitors.
IRAK-1KD was immunoprecipitated for 2 h at 4
 
	
 
C with an
anti–IRAK-1 antibody (Qbiogene), followed by the addition of
protein A trisacryl (Pierce Chemical Co.). Immune complexes
were washed twice with lysis buffer and twice with kinase buffer
containing 20 mM Tris-HCl, pH 7.5, 50 mM KCl, 2 mM
MgCl
 
2
 
, 2 mM MnCl
 
2
 
, 5% glycerol, and protease inhibitors. Af-
ter the last wash, immune complexes were resuspended in 40 
 

 
l
kinase buffer. For each kinase reaction 10 
 

 
l of the respective
immune complexes were mixed with 5 
 

 
Ci of [
 


 
-
 
32
 
P] ATP
(3,000 Ci/mmol) in a total volume of 25 
 

 
l. Reactions were al-
lowed to proceed for 15 min at 30
 
	
 
C and then directly analyzed
by SDS-PAGE and autoradiography. A reaction without ATP
added was set up in parallel and analyzed by Western blot to es-
timate the input.
 
Results and Discussion
 
The ID of MyD88 Is Critical for IRAK-1 Phosphoryla-
tion.
 
Initially, to prove that MyD88’s ID is indeed crucial
for IRAK-1 phosphorylation, a MyD88
 
 
 
MEF cell line
was generated and stably reconstituted with MyD88- or
MyD88s-expressing vectors, referred to here as MEF
 

 
MyD88 or MEF
 
 
 
MyD88s. The cells were stimulated with
IL-1
 
 
 
and IRAK-1 levels were monitored (as a readout for
phosphorylation-induced degradation) in total cell extracts
by Western blot analysis (Fig. 1 A). As previously reported,
IRAK-1 was not activated in MyD88
 
 
 
cells (15, 16).
Figure 1. The ID of MyD88 is critical for IRAK-1 phosphorylation. (A)
MyD88-deficient MEF cell line was reconstituted by retroviral infection
with an empty vector, MyD88, or MyD88s expression vectors. Reconsti-
tuted populations of cells are referred to as MEF vector, MEF MyD88,
and MEF MyD88s and were stimulated with 10 ng/ml IL-1 for 0.5 or
16 h. Total cell lysates were prepared and IRAK-1 levels were monitored
by Western blotting with anti–IRAK-1 antibodies. The levels of MyD88
or MyD88s in MEF MyD88 and MEF MyD88s cells were confirmed by
Western analysis with anti-MyD88 antibodies (middle). The loading con-
trol shows a nonspecific band detected by the anti-IRAK antibody. (B)
MEF vector, MEF MyD88, and MEF MyD88s cells were stimulated
with IL-1 or TNF for the indicated times. Reconstitution of MyD88-
deficient MEFs with MyD88 but not MyD88s restores NF-B signaling
as evidenced by IB degradation, which was monitored by Western anal-
ysis with anti-IB antibodies. In both MEF vector and MEF MyD88s
cells the IB degradation machinery is intact as evidenced by treatment
with TNF.
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However, activation of IRAK-1 was restored in the MEF
 

 
MyD88 cells as evidenced by the disappearance of IRAK-1
in an IL-1
 

 
–dependent manner. Even in the unstimulated
MEF
 
 
 
MyD88 cells, very little IRAK-1 was detected dem-
onstrating the effect that MyD88 overexpression alone has
on IRAK-1 stability. In contrast, IRAK-1 levels in MEF
 

 
MyD88s cells were comparable to those in control cells,
confirming that expression of MyD88s does not trigger
IRAK-1 phosphorylation and that the ID is essential for
IRAK-1 phosphorylation. The ID of MyD88 is also essen-
tial for IL-1
 

 
–induced NF-
 

 
B activation, based on the ab-
sence of I
 

 
B degradation in MEF
 
 
 
MyD88s cells stimulated
with IL-1
 
 
 
(Fig. 1 B).
 
MyD88 Is Required for IRAK-4–induced IRAK-1 Phos-
phorylation.
 
For sometime it was speculated that IRAK-1
was phosphorylated via its own kinase activity. However,
this idea was challenged by the discovery that a kinase-dead
mutant of IRAK-1 (subsequently referred to as IRAK-
1KD) was phosphorylated in an IRAK-1–deficient cell line
(17). A second kinase was postulated to phosphorylate
IRAK-1 and perhaps to activate IRAK-1’s own kinase ac-
tivity. Recently, IRAK-4, so called for its homology to
other members of the IRAK-1 family (other members in-
clude the kinase-inactive IRAK-2 and IRAK-M/3), was
identified as a candidate for the IRAK-1 kinase (18–20).
This was based on in vitro kinase assays and the observation
that IL-1–induced degradation of IRAK-1 was partially
blocked by overexpression of a kinase-inactive mutant
of IRAK-4 (20). IRAK-4–deficient mice confirm that
IRAK-4 is critical for signaling of IL-1 and TLR ligands
(21) and in contrast to other IRAKs, IRAK-4 appears to
require its kinase activity for signal transmission (20).
To obtain additional evidence that IRAK-4 is a kinase for
IRAK-1, we developed a simple coexpression assay in HEK
293T cells. IRAK-4 was cotransfected with IRAK-1KD
(IRAK-1D340N; used because it cannot self-phosphorylate
like overexpressed wild-type IRAK-1) and phosphorylation
monitored by the appearance of a slower migrating species
in SDS-PAGE. As predicted, IRAK-4 induced phosphory-
lation of IRAK-1KD (Fig. 2 A). That phosphorylation was
specifically induced by IRAK-4 was confirmed by the ob-
servation that coexpression of IRAK-1KD with two differ-
ent IRAK-4 kinase-dead mutants, IRAK-4KD (IRAK-
4KK213AA or IRAK-4D311N), did not similarly induce
IRAK-1KD phosphorylation (Fig. 2 A and unpublished
data). Although coexpression of IRAK-4 clearly induced
IRAK-1 phosphorylation, only a partial conversion to the
phosphorylated species was observed. The addition of
MyD88, however, significantly enhanced IRAK-4–induced
IRAK-1KD phosphorylation, suggesting that MyD88 stim-
ulates IRAK-4’s activity (Fig. 2, A and B). This was con-
firmed by an in vitro kinase assay (Fig. 2 B) performed on
immunoprecipitated IRAK-1KD showing significant phos-
phorylation of IRAK-1KD when immunoprecipitated from
cell extracts coexpressing MyD88 and IRAK-4, but not
IRAK-4KD (compare lane 1 with lanes 3 and 5).
As MyD88 binds to IRAK-1KD (MyD88 does not bind
the hyperphosphorylated form of IRAK-1 induced by its
overexpression; references 19 and 22) and was recently re-
ported to bind IRAK-4 (20), the simplest explanation for
the observed finding was that MyD88 modulates contact of
IRAK-1 and IRAK–4. To test this, IRAK-1KD and
IRAK-4 interactions were analyzed in the presence or ab-
sence of MyD88 and/or MyD88s (Fig. 2 C). As previously
Figure 2. IRAK-4–induced IRAK-1 phosphorylation is regulated by
MyD88/MyD88s. (A) IRAK-1KD (IRAK-1D340N) was cotransfected
in 293T cells with the indicated expression vectors. Total cell lysates were
prepared, separated by 10% SDS-PAGE, and analyzed by Western blot-
ting with anti–IRAK-1 antibodies. Expression of IRAK-4, MyD88, and/
or MyD88s was confirmed by Western analysis with the appropriate anti-
bodies. (B) IRAK-1KD was immunoprecipitated from cell extracts coex-
pressing the indicated proteins and then subjected to an in vitro kinase
assay. Phosphorylation of IRAK-1KD was then detected after SDS-
PAGE and autoradiography (top). The expression levels of the indicated
proteins (bottom panels), transfected as in the top panel lanes 1–5, were
confirmed by Western blotting with the appropriate antibodies. (C)
IRAK-4 was coimmunoprecipitated using an anti-Flag antibody from ly-
sates of 293T cells cotransfected with the indicated combinations of ex-
pression plasmids and immunoblotted with an anti–IRAK-1 antibody
(top). On the middle and bottom, Western blotting of cell lysates using
anti–IRAK-1, anti-Flag, and anti-E antibodies to detect IRAK-1KD,
IRAK-4, and MyD88/MyD88s, respectively, is shown. IP, immunopre-
cipitate; WB, Western blot.
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reported, IRAK-4 and IRAK-1KD do not directly associ-
ate (20). However, the addition of MyD88 but not
MyD88s (discussed below) permitted assembly of a com-
plex containing both IRAKs. MyD88 thereby appears to
act like a hinge inducing the proximity of IRAK-1 and
IRAK-4. Interestingly, phosphorylated IRAK-1 is stably
detected together with MyD88, IRAK-1, and IRAK-4,
suggesting that MyD88–IRAK-1 interactions are destabi-
lized only after multiple sites are phosphorylated on IRAK-1
(Fig. 2 C).
 
MyD88s Blocks IRAK-4–induced IRAK-1 Phosphoryla-
tion.
 
Unlike MyD88, MyD88s does not stimulate IRAK-
4–induced IRAK-1KD phosphorylation (Fig. 2, A and B).
In fact, in vitro phosphorylation of IRAK-1KD induced by
IRAK-4 coexpression was completely inhibited when
MyD88s was coexpressed (Fig. 2 B, compare lanes 2 and
4). In addition, MyD88s inhibited MyD88’s stimulatory ef-
fect on IRAK-4–induced IRAK-1KD phosphorylation in
a dose-dependent manner (Fig. 2 A).
 
MyD88s Does not Bind to IRAK-4 and Blocks Recruitment
of IRAK-4 to the IL-1Rs.
 
To characterize the underlying
mechanism by which MyD88s blocks IRAK-1 phosphory-
lation, we initially analyzed if MyD88 and IRAK-4 associ-
 
Figure 3.
 
MyD88s does not bind IRAK-4 and blocks its recruitment
to the IL-1Rs. (A) The left side of the top panel shows that IRAK-4 was
coimmunoprecipitated using an anti-VSV antibody from lysates of 293T
cells transfected with the indicated expression plasmids, and immuno-
blotted with an anti-Flag antibody. The middle and bottom panels show
Western blotting of immunoprecipitates and cell lysates, respectively, us-
ing anti-VSV or anti-MyD88 antibodies. The ride side of the top panel
shows that MyD88 was coimmunoprecipitated using an anti-E antibody
from lysates of 293T cells cotransfected with the indicated expression
plasmids, and immunoblotted with an anti–IRAK-1 antibody. The mid-
dle and bottom panels show Western blotting of immunoprecipitates or
cell lysates using anti-E (middle) or anti–IRAK-1 (bottom) antibodies. IP,
immunoprecipitate; WB, Western blot. (B) HF7c yeast was cotrans-
formed with expression vectors encoding the pGBT9 GAL4 DNA-bind-
ing domain fused to various MyD88 deletion mutants (schematically illus-
trated) and pGAD10 IRAK-4 expressing the GAL4 transcription
activation domain fused to full-length IRAK-4. Interaction of the pro-
teins was assessed by 
 
 
 
galactosidase expression filter assays. 
 
 
 
indicates
strong color development within 60 min of the assay and 
 
 
 
indicates no
development of color within 24 h. All pGBT9 fusion proteins were
checked for autoactivation and found to be negative. (C) Flag-tagged
IL-1Rs were coimmunoprecipitated with anti-Flag antibodies from ly-
sates of 293T cells cotransfected with the indicated expression plasmids
and immunoblotted with an anti-Xpress antibody to detect IRAK-4KD
association. The same blot was reprobed with anti-Flag, anti-E, and anti–
IRAK-1 antibodies to monitor IL-1Rs, MyD88, and IRAK-1KD levels,
respectively. Bottom panels show Western blotting of cell lysates using
the indicated antibodies.
Figure 4. Model for MyD88/MyD88s regulation of IRAK-4–induced
IRAK-1 phosphorylation. On the left, MyD88 links IRAK-1 with
IRAK-4–activating NF-B. IL-1 stimulation of the IL-1Rs induces as-
sembly of a signaling complex containing MyD88 and IRAK-1 and
IRAK-4. Dimers of MyD88 bind IRAK-1 and IRAK-4 bringing the re-
spective kinase domains in close association (step 1). This results in the
phosphorylation of IRAK-1 by IRAK-4, which in turn likely induces the
kinase activity of IRAK-1 leading to its autophosphorylation (step 2).
IRAK-4 is depicted activated at the IL-1Rs but this has not been formally
demonstrated. Phosphorylated IRAK-1 first binds TNFR-associated fac-
tor 6 (not depicted) activating NF-B and then is ubiquitinated (multiple
arrows attached to IRAK-1) and degraded. For simplicity, other adaptor
molecules such as Tollip have been omitted (12). On the right, inhibition
of IL-1 signaling by MyD88s is shown. MyD88s (depicted as a shorter
molecule missing the ID) does not interact with IRAK-4. IRAK-4 is not
recruited to the IL-1Rs, thereby preventing the association of IRAK-1
and IRAK-4 and thus the phosphorylation of IRAK-1. As a result, there
is no NF-B activation.
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ate. We did not expect the contrary, considering that
MyD88 binds IRAK-1 primarily through DD–DD inter-
actions (19, 22, and unpublished data). Surprisingly,
MyD88s–IRAK-4 complexes were not detected (Fig. 3 A,
left), despite the strong association of MyD88s and IRAK-
1KD under similar conditions of coimmunoprecipitation
(Fig. 3 A, right). Therefore, this suggested that the ID of
MyD88 is required for this association with IRAK-4. To
confirm this, the precise region of MyD88 mediating its in-
teraction with IRAK-4 was mapped by yeast 2 hybrid and
coimmunoprecipitation binding assays (Fig. 3 B and un-
published data). These assays confirm that MyD88 does,
and MyD88s does not, interact with IRAK4. However,
the ID in itself is insufficient, suggesting that MyD88 inter-
acts with IRAK-4 via a peptide spanning both the ID and
adjacent amino acids in the DD (we cannot exclude that
the first 17 amino acids of the TIR are important for bind-
ing) or that the ID induces a conformation of MyD88, ex-
posing residues in the DD that are critical for interactions
between the two proteins.
Taken together, the results described above suggested
that MyD88s acts as a negative regulator by its incapacity to
bind to IRAK-4 and thus prevents IRAK-4–induced
IRAK-1 phosphorylation. IRAK-4 is presumably recruited
to the activated IL-1R complex raising the question of
whether MyD88s also blocks IRAK-4 recruitment to the
activated receptors. To address this question, coimmuno-
precipitation of the IL-1Rs with associating proteins
(MyD88, IRAK-1KD, and IRAK-4-KD) was performed
in the presence or absence of MyD88s and/or Tollip,
which we have previously shown to be important for
IRAK-1 recruitment to the IL-1Rs (12). More IRAK-4
was found to associate with the IL-1Rs in the presence of
Tollip, suggesting that Tollip may also be involved in
IRAK-4 recruitment (Fig. 3 C). However, despite Tollip,
the presence of MyD88s dramatically inhibited IRAK-4
but not IRAK-1 association with the IL-1Rs (Fig. 3 C).
In summary, we have demonstrated why the ID of
MyD88 is critical for the activation of NF-
 

 
B. Via this do-
main, MyD88 plays an active role in the phosphorylation
and activation of IRAK-1. Our results are compatible with
the following sequence of events (Fig. 4). After their re-
cruitment to the IL-1R–TLR complexes, MyD88, most
probably as a dimer (13), binds IRAK-1 and IRAK-4, in-
ducing the close proximity of the IRAK-1 and IRAK-4 ki-
nase domains. This in turn allows IRAK-4 to phosphory-
late critical residue(s) in the kinase activation loop of
IRAK-1, triggering IRAK-1’s own kinase activity. Threo-
nine-387 and Serine-376 are potential phosphorylation
sites in the activation loop of IRAK-1 based on the re-
duced ability of IRAK-4 to phosphorylate short peptides
with mutations at these residues (20). Once activated,
IRAK-1 likely autophosphorylates residues in its NH
 
2 
 
ter-
minus resulting in the hyperphosphorylated form detected
after stimulation (5, 9). It is this multiphosphorylated form
of IRAK-1 that is likely targeted for degradation (10). Un-
der chronic conditions of inflammation or after prolonged
exposure to LPS MyD88s is expressed (11). As a result, the
above sequence of events is halted. IRAK-4 is not re-
cruited to the IL-1Rs/TLRs and therefore IRAK-1 is not
phosphorylated/activated and as a consequence signal
transmission is interrupted. In conclusion, MyD88s acts as a
negative regulator of IL-1
 

 
/LPS-induced NF-
 

 
B activa-
tion by preventing IRAK-4’s access to its substrate.
Septic shock is characterized by tissue and organ damage
resulting from hyperproduction of cytokines. Septic shock
survivors have an increased incidence of bacterial infections
and suppressed monocyte responses to LPS. This “endo-
toxin tolerance” is a transient state of LPS refractoriness after
the initial, nonlethal exposure to LPS. An understanding of
the mechanisms that elicit endotoxin tolerance is critical for
unraveling the molecular basis of the septic shock syn-
drome, yet despite numerous studies these mechanisms re-
main largely unknown. Recently, it has been suggested that
IRAK-3 (IRAK-M) is a key component of this important
control system (23). IRAK-3 lacks kinase activity, is only
expressed upon prior endotoxin treatment, and blocks
TLR-induced signaling. IRAK-3–deficient cells, how-
ever, still retain some capacity to develop LPS tolerance,
indicating the presence of additional control mechanisms.
Aside from the proposed down-regulation of TLR4 (24),
MyD88s also appears to be a likely candidate for tolerance
induction as the expression of MyD88s is inducible by LPS
and TNF (11). Thus, MyD88s and IRAK-3 might both
contribute to endotoxin tolerance.
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